Matribhumi Samachar English
Highlights Newly granted patent protects TempraMed’s VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture Expands the Company’s ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics Enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in Asia’s premium …
Read More »TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership Vancouver, British Columbia–(Newsfile Corp. – December 10, 2025) – TempraMed Technologies Ltd. (CSE: VIVI) (“TempraMed” or the “Company“), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced …
Read More »TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, British Columbia–(Newsfile Corp. – December 8, 2025) – TempraMed Technologies Ltd. (CSE: VIVI) (“TempraMed” or the “Company“), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the …
Read More »TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance One of many distribution agreements …
Read More »